Firebrick receives $293,000 R&D Tax Incentive
Filed with ASX · · 1 page · English
Summary by 6ix AI
Firebrick Pharma Limited has announced the receipt of a research and development tax incentive payment, which is a significant non-dilutive funding source for the company. The incentive amounts to a substantial sum related to reported research and development costs associated with the development of new products in the Nasodine range. Dr. Peter Molloy, Executive Director, expressed appreciation for this valuable financial support.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Firebrick Pharma Limited on 6ix
Story so far
Earlier from Firebrick Pharma
- Appendix 4E and Annual Report 30 June 2026
- Investor Update
- March 2026 Quarterly Activity Report & Appendix 4C
- Firebrick Secures $1.5 million via Placement
- Trading Halt
Later from Firebrick Pharma
- Firebrick announces USA Retail Launch Plan
- Firebrick Secures $732k in Strategic Investments
- Nasodine Nasal Spray Approved in the Philippines
- New Product - Nasodine Sinus Rinse
- September 2026 Quarterly Activity Report & Appendix 4C
Follow Firebrick Pharma into a list and get an email when it puts out news.
Follow Firebrick Pharma